Diagnosis and treatment of benign intrauterine pathologies in postmenopausal patients

Курцер, М. А.; Бреусенко, В. Г.; Голухов, Г. Н.; Golova, Yu.А.; Esipova, I.А.; Ovchinnikova, A.V.; Lyafisheva, D.M.

doi:10.20953/1726-1678-2019-3-71-79

Vopr. ginekol. akuš. perinatol.

2019

DOI: 10.20953/1726-1678-2019-3-71-79

|View full text |Cite

Diagnosis and treatment of benign intrauterine pathologies in postmenopausal patients

М. А. Курцер¹,

В. Г. Бреусенко²,

Г. Н. Голухов³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A new strategy in selection of hormone therapy for endometrial proliferative process in postmenopausal patients

Savelieva

Бреусенко

et al. 2022

BRSMU

View full text Add to dashboard Cite

The limited efficacy of hormone therapy for endometrial proliferative process (EPP) in postmenopausal patients and its side effects on the immune system functionalities have not been studied in detail. Here we assess the feasibility of hormone therapy for EPP in postmenopausal patients through evaluation of estradiol and progesterone receptor gene expression in endometrial tissue and peripheral blood mononuclear cells (PBMC). The study enrolled 92 postmenopausal patients with EPP, including 37 pts with glandular-fibrous polyps, 7 pts with non-atypical endometrial hyperplasia (EH), 8 pts with atypical endometrial hyperplasia (AEH), 31 pts with moderately differentiated adenocarcinoma and 9 pts with highly differentiated adenocarcinoma. The PBMC isolates and endometrial samples were tested for ER⍺, ERβ, mER, PRA, PRB, mPR and PGRmC1 expression by reverse real time polymerase chain reaction (RT–PCR). Differential changes in PBMC receptor profiles upon in vitro exposure to progesterone or mifepristone were determined for patients with endometrial polyps and healthy women. The results indicate elevated expression of ERα, ERβ, PRA, PRB, mPR and PGRmC1 by endometrial tissues in EH and elevated expression of mER, ER⍺ and PRA by PBMC in AEH, apparently reflecting suppressed functionalities of monocytes, macrophages, Т-cells and natural killer cells. Unaltered expression of the studied genes by PBMC in endometrial adenocarcinoma may reflect the incrementing tumor autonomy. In vitro, mifepristone inhibited ER⍺, ERβ, mPR, PGRmC1, PRA and PRB expression in PBMC isolated from patients with endometrial polyps. We suppose that such effects can mitigate the negative influence of sex steroid hormones on immunocompetent cells.

show abstract

A new strategy in selection of hormone therapy for endometrial proliferative process in postmenopausal patients

Savelieva

Бреусенко

et al. 2022

BRSMU

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Diagnosis and treatment of benign intrauterine pathologies in postmenopausal patients

Cited by 1 publication

References 0 publications

A new strategy in selection of hormone therapy for endometrial proliferative process in postmenopausal patients

A new strategy in selection of hormone therapy for endometrial proliferative process in postmenopausal patients

Contact Info

Product

Resources

About